World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
63
Citations
22252
World Ranking
9998
National Ranking
4378

Overview

Tim Clackson is a researcher affiliated with Theseus Pharmaceuticals in the United States, specializing primarily in Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans multiple subfields, including Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Pathology and Forensic Medicine, and Radiology, Nuclear Medicine and Imaging.

The main topics of Clackson's research encompass Lung Cancer Treatments and Mutations, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy, Colorectal Cancer Treatments and Studies, Monoclonal and Polyclonal Antibodies Research, Peptidase Inhibition and Analysis, and Inflammatory mediators and NSAID effects.

Clackson has been involved in several recent publications, contributing to the landscape of cancer research and immunotherapy. Notable papers include:

  • "Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer," 2021, Cancer Discovery
  • "Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer," 2022, Bioorganic & Medicinal Chemistry Letters
  • "XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer," 2023, Journal for ImmunoTherapy of Cancer
  • "568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates," 2020, Regular and Young Investigator Award Abstracts

Frequent coauthors in Clackson's research include Francois Gonzalvez, Theresa E. Baker, Alexandra E. Gould, Scott Wardwell, and Sara Nadworny, each collaborating on at least two publications. Publication venues associated with Clackson's work include Cancer Discovery, Bioorganic & Medicinal Chemistry Letters, Journal for ImmunoTherapy of Cancer, and Regular and Young Investigator Award Abstracts.

Best Publications

  • A hot spot of binding energy in a hormone-receptor interface

    Tim Clackson;James A. Wells

  • Making antibody fragments using phage display libraries

    Tim Clackson;Hennie R. Hoogenboom;Andrew D. Griffiths;Greg Winter

  • AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Thomas O'Hare;Thomas O'Hare;William C. Shakespeare;Xiaotian Zhu;Christopher A. Eide;Christopher A. Eide

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • By-passing immunization: building high affinity human antibodies by chain shuffling.

    James D. Marks;Andrew D. Griffiths;Magnus Malmqvist;Tim P. Clackson

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • A HUMANIZED SYSTEM FOR PHARMACOLOGIC CONTROL OF GENE EXPRESSION

    Victor M. Rivera;Tim Clackson;Sridaran Natesan;Roy Pollock

  • Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity

    Tim Clackson;Wu Yang;Leonard W. Rozamus;Marcos Hatada

  • In vitro selection from protein and peptide libraries

    Tim Clackson;James A. Wells

  • Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

    Wei-Sheng Huang;Chester A Metcalf;Raji Sundaramoorthi;Yihan Wang

  • Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum

    Victor M. Rivera;Xiurong Wang;Scott Wardwell;Nancy L. Courage

  • Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

    Wei-Sheng Huang;Shuangying Liu;Dong Zou;Mathew Thomas

  • The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.

    Sen Zhang;Rana Anjum;Rachel Squillace;Sara Nadworny

  • Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity.

    T Clackson;M.H Ultsch;J.A Wells;A.M. de Vos

  • Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

    Scott N Gettinger;Lyudmila A Bazhenova;Corey J Langer;Ravi Salgia

  • Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

    Joseph M Gozgit;Matthew J Wong;Lauren Moran;Scott Wardwell

  • Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer

    Victor M. Rivera;Guang-ping Gao;Rebecca L. Grant;Michael A. Schnell

  • Mutations of the Growth Hormone Receptor in Children with Idiopathic Short Stature

    Audrey D. Goddard;Robin Covello;Shiuh-Ming Luoh;Tim Clackson

  • Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

    Tianjun Zhou;Lois Commodore;Wei-Sheng Huang;Yihan Wang

  • Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

    Sant P. Chawla;Arthur P. Staddon;Laurence H. Baker;Scott M. Schuetze

Frequent Co-Authors

Victor M. Rivera
Victor M. Rivera Takeda (Japan)
Michael W. Deininger
Michael W. Deininger University of Utah
Jorge E. Cortes
Jorge E. Cortes Augusta University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Neil P. Shah
Neil P. Shah University of California, San Francisco
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Michele Baccarani
Michele Baccarani University of Bologna
Francois Guilhot
Francois Guilhot Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing studies in Biology and Biochemistry opens doors to a variety of related online degrees and professional pathways. If you’re interested in how the human body moves and functions, online kinesiology programs can complement your background, leading to roles in sports science or physical therapy.

For those considering healthcare careers, bridging programs such as the 1 year pmhnp program online or online fnp programs help biology and biochemistry graduates fast-track to advanced nursing or practitioner roles. These flexible study options let you gain new qualifications while working.

Nutrition is another growing field tied closely to biology. For those who want to become registered dietitians, online learning is accessible through a online dietitian degree. This provides a direct pathway to working in clinical, wellness, or food science settings.

Exploring these online degrees expands your career options, letting you turn a strong foundation in Biology and Biochemistry into rewarding health, research, and wellness professions.

Best Scientists Citing Tim Clackson

Trending Scientists

Recently Published Articles